Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
What does it do?
Novo Nordisk is a Danish pharmaceutical company best known for making Ozempic and Wegovy — the blockbuster drugs you've probably seen all over the news for treating diabetes and obesity. Think of them as the company that figured out how to help people lose significant amounts of weight with a weekly injection, not just manage blood sugar. They also make insulin and treatments for rare diseases like hemophilia. They're one of the largest companies in Europe by market value.
The global obesity epidemic affects over one billion people, and Novo Nordisk is currently the dominant player in a drug category that many analysts believe could become one of the biggest in pharmaceutical history. Investor excitement is enormous but so is the pressure — the stock has come down significantly from its 2024 peak as clinical trial results disappointed and competition heated up. This is a company at a genuine inflection point: either it cements its lead or rivals start taking real market share.
How does it make money?
Novo Nordisk makes money by selling prescription drugs, primarily through its Obesity and Diabetes Care segment which includes Ozempic (for type 2 diabetes), Wegovy (for obesity), and Rybelsus (an oral diabetes pill). These three products alone drive the vast majority of revenue. Annual revenue hit $309 billion Danish krone (roughly $44 billion USD), up from $290 billion the prior year — a healthy growth rate of around 6%. Their Rare Disease segment, covering hemophilia and hormone disorders, is a smaller but stable revenue contributor.
Why do investors care?
The investment case rests on one big bet: that GLP-1 drugs (the class Ozempic and Wegovy belong to) will become as widespread as statins for cholesterol, taken by hundreds of millions of people long-term. If that happens, Novo Nordisk's early lead in manufacturing scale and brand recognition could translate into decades of strong earnings. What has to go right is that Wegovy continues to show benefits beyond weight loss — like reducing heart attacks — which would push insurers and governments to cover it more broadly, and that Novo Nordisk stays ahead of competitors in next-generation formulations.
Deep Dive
MemberA full investor briefing on Novo Nordisk A/S — history, leadership, risks, and outlook.